Adjuvance Technologies

[Available On-Demand]
Adjuvance Technologies is a privately held biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in vaccine adjuvant design and manufacturing. Adjuvants are critical components that improve the immune response of many vaccines. Adjuvance Technologies has developed the ability to synthesize next-generation saponin adjuvants such as those used in shingles, malaria, flu and COVID-19 vaccines. Its lead adjuvant candidate, TQL-1055, is designed to provide strong improvement in immune response with fewer adverse events after vaccination. TQL-1055 is in pre-clinical development for multiple indications in infectious disease, oncology, neurobiology, substance abuse, and allergy.

Adjuvance will have first-in-human data in mid-2021 and is planning a Series B financing in late 2021.
Company Type:
Company HQ State:
Nebraska
Company HQ Country:
United States
Year Founded:
2009
Main Therapeutic Focus:
Lead Product in Development:
next-generation saponin adjuvant TQL-1055
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
CEO
Adjuvance Technologies, Inc.